PietroRavani University of CalgaryCanada

PietroRavani
Dr. Pietro Ravani is a Professor and Clinician Scientist in the Department of Medicine and Institute of Public Health at the University of Calgary. Dr. Ravani received his medical training at the University of Parma, Italy, and completed a Master’s of Science in Biostatistics at the University of Pavia, Italy, followed by a PhD in Clinical Epidemiology at Memorial University in Newfoundland. Dr. Ravani worked as a practicing physician in Italy until 2008, when he moved to Calgary. His research interests include statistical methods in outcomes research and design of clinical trials and longitudinal studies in kidney disease.
Institution

Day 2 - Monday April 15, 2024

Time Session
9 a.m.
10:30 a.m.
Insights From Understanding Heterogeneous Trajectories to Kidney Failure
FacundoDaminato Chairperson fmdaminato@hotmail.comArgentina
Magdalena Madero Chairperson Chief of Nephrology, Instituto Nacional de CardiolMexico
PietroRavani Chairperson pravani@ucalgary.caUniversity of CalgaryCanada
  • Non-neoplastic Lesions in Nephrectomy Samples: Implications for Kidney Function
    JairMunoz Mendoza Speaker JMMendoza@med.miami.eduUniversity of MiamiUnited States
  • Understanding the Heterogeneous Trajectory of CKD
    MorganGrams Speaker morgan.grams@nyulangone.orgNew York UniversityUnited States
  • Review of Medical Therapies Proven to Delay CKD Progression
    DoreenZhu Speaker doreen.zhu@ndph.ox.ac.ukUniversity of OxfordUnited Kingdom
  • Impact of Obesity and Novel Treatment Strategies on CKD Progression
    PeterRossing Speaker Steno Diabetes Center Copenhagen Denmark
  • Q and A
Hall C4
3 p.m.
4 p.m.
Late Breaking Clinical Trials Session
AlessiaFornoni Chairperson United States
MichelleRheault Chairperson rheau002@umn.eduUniversity of MinnesotaUnited States
  • Predicting the Risks of Kidney Failure and Death in Adults With Moderate-to-severe Chronic Kidney Disease (KDpredict)
    PietroRavani Free Communication pravani@ucalgary.caUniversity of CalgaryCanada
  • Plasma Exchange in ANCA Associated Vasculitis GN: Update After Pexivas
    Wladimir MietekSzpirt Speaker wladimir.mietek.szpirt.01@regionh.dkRigshospitalet, University of Copenhagen, Dept. of Nephrology, Denmark, Senior Research ConsultantDenmark
  • EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY
    DanaRizk Free Communication drizk@uabmc.eduUniversity of Alabama at BirminghamUnited States
  • SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL
    JonathanBarratt Free Communication University of Leicester, Leicester, UKUnited Kingdom
  • PREGNANCY AMONG WOMEN ON CHRONIC DIALYSIS : THE FRENCH COHORT
    CécileCouchoud Free Communication cecile.couchoud@biomedecine.frREIN registry, Agence de la biomédecine, FranceFrance
Hall A